At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study - Summary - MDSpire

Telehealth-Enabled Subcutaneous Ketamine Treatment at Home: Evaluating Safety, Feasibility, and Clinical Outcomes in Adults with Moderate to Severe Depression, Anxiety, or PTSD in a Diverse U.S. Cohort - A Retrospective Study

  • By

  • Acacia C Parks

  • Amanda L Woodward

  • Robert D Henry

  • Kristin A Arden

  • Leonardo Vando

  • Jack Swain

  • Bishal Lamichhane

  • July 20, 2026

Share

Objective:

To evaluate the safety, feasibility, and clinical outcomes of telehealth-enabled subcutaneous ketamine treatment at home for adults with moderate to severe depression, anxiety, or PTSD.

Approach:
  • Study Design: A retrospective study assessing the outcomes of telehealth-enabled subcutaneous ketamine treatment.
  • Population: Diverse U.S. cohort of adults diagnosed with moderate to severe depression, anxiety, or PTSD.
Key Findings:
  • Telehealth-enabled ketamine treatment was found to be safe and feasible for home administration.
  • Clinical outcomes indicated improvements in symptoms of depression, anxiety, and PTSD among participants.
Interpretation:

Limitations:
  • Retrospective design may limit the ability to establish causality.
  • Potential selection bias in the cohort may affect generalizability.
Conclusion:

Original Source(s)

Related Content